清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism

医学 阿哌沙班 拜瑞妥 华法林 危险系数 中止 内科学 队列 队列研究 倾向得分匹配 人口 比例危险模型 重症监护医学 急诊医学 心房颤动 置信区间 环境卫生
作者
Sungho Bea,Geetha Iyer,Dae‐Hyun Kim,Kueiyu Joshua Lin,Yichi Zhang,Heidi Zakoul,Helen Tesfaye,Katsiaryna Bykov
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:185 (7): 837-837 被引量:25
标识
DOI:10.1001/jamainternmed.2025.1109
摘要

Importance: Over the past decade, there has been a considerable shift in the use of pharmacologic agents for venous thromboembolism (VTE), with direct oral anticoagulants replacing warfarin as the drugs of choice for VTE recurrence prevention; however, evidence from head-to-head comparison studies remains limited. Objective: To compare the effectiveness and safety of 3 common oral anticoagulants (apixaban, rivaroxaban, and warfarin) in patients with VTE. Design, Setting, and Participants: This population-based cohort study used Medicare and 2 commercial insurance databases from 2016 up to 2024 to identify patients 18 years and older who initiated an oral anticoagulant following VTE and had at least 1 year of continuous insurance enrollment before the index date. Exposure: Initiation of apixaban, rivaroxaban, or warfarin within 30 days after VTE discharge. Main Outcomes and Measures: The primary effectiveness outcome was hospitalization for recurrent VTE. The primary safety outcome was major bleeding. Patients were followed up from treatment initiation until outcome occurrence, treatment discontinuation/switch, disenrollment, death, or end of available data. Propensity score-matching weights were used to adjust for confounding. Weighted Cox proportional hazard models estimated weighted hazard ratios (HRs) and 95% CIs. Results: Among 163 593 eligible individuals (mean [SD] age, 71.4 [13.5] years; 56.7% female), 58.5% initiated apixaban, 25.7% initiated rivaroxaban, and 15.8% initiated warfarin. Overall, 3270 hospitalizations for recurrent VTE and 4229 hospitalizations for bleeding events occurred. Compared with warfarin, patients taking apixaban (HR, 0.67; 95% CI, 0.61-0.75) and rivaroxaban (HR, 0.77; 95% CI, 0.69-0.87) had a lower risk of recurrent VTE. Apixaban showed a further decrease in risk compared with rivaroxaban (HR, 0.87; 95% CI, 0.78-0.96). Patients taking apixaban also had a lower risk of major bleeding compared with warfarin (HR, 0.70; 95% CI, 0.64-0.76) and rivaroxaban (HR, 0.69; 95% CI, 0.63-0.75). No difference in bleeding risk was observed between rivaroxaban and warfarin (HR, 1.02; 95% CI, 0.92-1.12). These findings were consistent across subgroups defined by age, sex, cancer, chronic kidney disease, bleeding history, and frailty. Conclusions and Relevance: In this cohort study of patients with VTE who initiated an oral anticoagulant, apixaban was associated with a lower risk of VTE recurrence and major bleeding compared with rivaroxaban and warfarin. These results provide evidence to guide the selection of appropriate initial oral anticoagulant regimens for adult patients with VTE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
端庄的如松完成签到,获得积分10
刚刚
皮卡皮卡皮卡丘完成签到,获得积分10
1秒前
Maestro_S的应助被科研通管家采纳,获得10
2秒前
null的应助被科研通管家采纳,获得10
3秒前
花开富贵完成签到,获得积分10
4秒前
luyu完成签到,获得积分10
4秒前
mayberichard完成签到,获得积分10
4秒前
热情善斓完成签到,获得积分10
5秒前
dianeil发布了新的文献求助10
5秒前
hh完成签到,获得积分10
7秒前
昊儿虫完成签到,获得积分10
7秒前
宝哥完成签到,获得积分10
7秒前
顺心雁开完成签到,获得积分10
10秒前
Cling5899完成签到,获得积分10
11秒前
bao完成签到,获得积分10
12秒前
小冯完成签到,获得积分10
16秒前
fomo完成签到,获得积分0
17秒前
坦率钢笔完成签到,获得积分10
18秒前
yuan完成签到,获得积分10
19秒前
精明开山完成签到,获得积分10
22秒前
刘沂卓完成签到,获得积分10
24秒前
suda完成签到,获得积分10
28秒前
怡然的千儿完成签到,获得积分10
31秒前
MIO完成签到,获得积分10
33秒前
美满的水卉完成签到,获得积分10
33秒前
是丹小朱呀完成签到,获得积分10
34秒前
夏月虚闲完成签到,获得积分10
35秒前
yuxuan1完成签到,获得积分10
36秒前
yuxuan完成签到,获得积分10
40秒前
cxf完成签到,获得积分10
43秒前
Asumita完成签到,获得积分10
49秒前
啵啵椰完成签到,获得积分10
1分钟前
简单代梅完成签到,获得积分10
1分钟前
1分钟前
顺利的雅旋完成签到,获得积分10
1分钟前
善良的金鱼完成签到,获得积分10
1分钟前
初景发布了新的文献求助10
1分钟前
null的应助被科研通管家采纳,获得10
2分钟前
高高仙人掌完成签到,获得积分10
2分钟前
殷勤的半凡完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280